Conditions: Breast Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 257
Healthy volunteers: no

Brief summary:
An open-label randomized Phase II study in order to explore two different sequential anthracycline-based neoadjuvant treatment regimens in female patients with primary, operable breast cancer (T2-T4/N0-2/M0).

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: pemetrexed intervention 2: cyclophosphamide intervention 3: doxorubicin intervention 4: docetaxel
Intervention descriptions: intervention 1: 500 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4) intervention 2: 600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4) intervention 3: 60 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4) intervention 4: 100 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (5-8)

Protocol document: